It has been reported that triple negative breast cancer (TNBC) makes up approximately 15%-20% of all BC patients, which is characterized by estrogen (ER), progesterone (PR), and human epidermal growth factor receptor-2 (HER2) negativity (2). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.